Cash Flow Statement (Annual)
LJPC / La Jolla Pharmaceutical Co. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Net Cash Provided By Used In Operating Activities|
|Net Income Loss||-3,760||-11,548||-7,737||-17,935||-21,313||-41,912||-78,185||-114,803|
|Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities|
|Share Based Compensation||489||254||8,604||12,373||8,992||11,551||14,349||20,776|
|Gain Loss On Disposition Of Assets1||-||-||-||0||0||-16||-75||-199|
|Increase Decrease In Operating Capital|
|Increase Decrease In Inventories And Other Operating Assets||-||-||-||-||-||-||-||-|
|Increase Decrease In Prepaid Deferred Expense And Other Assets||-519||-7||-35||18||94||-824||664||1,642|
|Increase Decrease In Other Operating Assets||-||-||-||0||0||70||149||-219|
|Increase Decrease In Accounts Payable And Accrued Liabilities||-231||31||-49||822||-104||2,322||3,600||4,832|
|Increase Decrease In Accrued Liabilities And Other Operating Liabilities||-||-||-||80||739||-248||227||-202|
|Increase Decrease In Employee Related Liabilities||-88||-78||10||56||324||666||987||2,918|
|Increase Decrease In Deferred Rent||-||-||-||-||-||0||124||335|
|Net Cash Provided By Used In Operating Activities||-3,391||-1,826||-2,135||-4,734||-12,879||-25,183||-58,672||-84,881|
|Net Cash Provided By Used In Investing Activities|
|Payments To Acquire Property Plant And Equipment||-||-||0||43||258||1,816||2,218||9,194|
|Net Cash Provided By Used In Investing Activities||-||-||0||-43||-258||-1,816||-2,218||-9,194|
|Net Cash Provided By Used In Financing Activities|
|Proceeds From Issuance Of Common Stock||-||-||0||6,751||53,063||104,596||0||117,480|
|Proceeds From Stock Options Exercised||-||0||0||0||0||315||149||2,693|
|Net Cash Provided By Used In Financing Activities||6,003||-||500||10,001||53,063||104,911||149||119,264|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect||-||-||-||-||-||-||-||-|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents||-||-||-||-||-||-||-||-|
|Cash Cash Equivalents And Short Term Investments|
|Cash And Cash Equivalents At Carrying Value||-||5,040||3,405||8,629||48,555||126,467||65,726||90,915|
|Restricted Cash Current||-||-||-||-||-||-||-||-|
|Restricted Cash Noncurrent||-||-||-||-||-||-||-||-|
Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)
APEN / Apollo Endosurgery Inc.
ARIA / ARIAD Pharmaceuticals, Inc.
AVIR / Aviragen Therapeutics, Inc.
AVXS / AveXis, Inc.
BOTA / Biota Pharmaceuticals, Inc.
CASI / CASI Pharmaceuticals, Inc.
CYTR / CytRx Corp.
EIGR / Eiger BioPharmaceuticals, Inc.
FENC / Fennec Pharmaceuticals Inc.
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET